Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sixun Yang

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|August 12, 2008
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cellsSixun Yang, Jeffrey Schlom
Journal of Immunology (Baltimore, Md. : 1950)|March 23, 2004
Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathwaysSixun Yang, Frank G Haluska
JAMA|June 5, 2025
Pausing Chikungunya Vaccination and Accelerated ApprovalVinay Prasad, David C Kaslow, Sixun Yang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cellsSixun Yang, Kwong-Yok Tsang, Jeffrey Schlom
Vaccine|August 2, 2017
Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virusSixun Yang, Doran Fink, Andrea Hulse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR aviditySixun Yang, Gerald P Linette, Simonne Longerich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Vaccines with enhanced costimulation maintain high avidity memory CTLSixun Yang, James W Hodge, Douglas W Grosenbach, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2020
End Points for Clinical Trials in Primary HyperoxaluriaDawn S Milliner, Tracy L McGregor, Aliza Thompson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2023
End Point Considerations for Clinical Trials in Enteric HyperoxaluriaCraig B Langman, Dean Assimos, Melanie Blank, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|August 12, 2008
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cellsSixun Yang, Jeffrey Schlom
Journal of Immunology (Baltimore, Md. : 1950)|March 23, 2004
Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathwaysSixun Yang, Frank G Haluska
JAMA|June 5, 2025
Pausing Chikungunya Vaccination and Accelerated ApprovalVinay Prasad, David C Kaslow, Sixun Yang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cellsSixun Yang, Kwong-Yok Tsang, Jeffrey Schlom
Vaccine|August 2, 2017
Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virusSixun Yang, Doran Fink, Andrea Hulse, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR aviditySixun Yang, Gerald P Linette, Simonne Longerich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Vaccines with enhanced costimulation maintain high avidity memory CTLSixun Yang, James W Hodge, Douglas W Grosenbach, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2020
End Points for Clinical Trials in Primary HyperoxaluriaDawn S Milliner, Tracy L McGregor, Aliza Thompson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 21, 2023
End Point Considerations for Clinical Trials in Enteric HyperoxaluriaCraig B Langman, Dean Assimos, Melanie Blank, et al.
Pageof 1